Full Answer
Does Pfizer offer financial support for patients with Inflectra?
Patient Support for INFLECTRA Pfizer offers financial support programs to assist patients with accessing INFLECTRA treatment, including: Pfizer enCompass™ Co-Pay Assistance Program for INFLECTRA – For patients with commercial insurance that covers INFLECTRA
What is Inflectra encompass co-pay assistance program?
Inflectra enCompass Co-Pay Assistance Program: Eligible commercially insured patients may pay $0 co-pay per prescription with savings of up to $20,000 per calendar year; for additional information contact the program at 844-722-6672.
Who can investigate patients'insurance benefits and coverage details for Inflectra?
Pfizer enCompass™ Access Counselors can investigate patients' insurance benefits and coverage details for INFLECTRA *Administered by ConnectiveRx. See program full terms and conditions below. †For eligible patients.
What is the Pfizer encompass co-pay assistance program?
The Pfizer enCompass Co-Pay Assistance Program provides eligible, commercially insured patients assistance of up to $20,000 for INFLECTRA and $25,000 for RUXIENCE per calendar year for claims received by the program. Eligible enrolled patients may pay as little as $0 for each INFLECTRA or RUXIENCE treatment.
Does INFLECTRA have copay assistance?
The Pfizer enCompass Co-Pay Assistance Program provides assistance for out-of-pocket drug costs associated with INFLECTRA due to co-pays, co-insurances, or deductibles, up to $20,000 per calendar year. You are responsible for the first $5 of each injection before the benefit may be used.
What is the name of Pfizer's patient assistance program for its infliximab biosimilar in the United States?
INFLECTRA® (infliximab-dyyb) for Healthcare professionals: Inflectra (infliximab – dyyb) for Injection U.S. Physician Prescribing Information.
What is the cost of INFLECTRA?
SEB infliximab (Inflectra) is available as a 100 mg/vial solution for intravenous infusion at a manufacturer submitted price of $525.00 pervial.
What is the Pfizer Patient Assistance Program?
Pfizer Patient Assistance Program Provides free Pfizer medicines to eligible patients through their doctor's office or at home. To qualify, patients must: Have a valid prescription for the Pfizer medicine for which they are seeking assistance.
How often do you get Inflectra infusions?
The recommended dosage of INFLECTRA is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adult patients with moderately to severely active UC.
Does Inflectra cause weight gain?
Conclusion: Approximately 60% of Crohn's disease patients experience weight gain within the first six weeks of infliximab treatment. The weight increment correlates with improvements in inflammatory markers and disease activity.
How much does INFLECTRA cost without insurance?
About Inflectra INFLIXIMAB is used to treat Crohn's disease and ulcerative colitis. It is also used to treat ankylosing spondylitis, plaque psoriasis, and some forms of arthritis. The lowest GoodRx price for the most common version of Inflectra is around $4,606.59, 32% off the average retail price of $6,783.11.
Is INFLECTRA covered by insurance?
Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), is now covered by Medicare and Medicaid. Approved by the Food and Drug Administration in April 2016, Inflectra is the first biosimilar indicated for the treatment of rheumatic and inflammatory diseases to come to market in the United States.
What is the success rate of INFLECTRA?
The response rates, 71.4% for INFLECTRA and 75.2% for REMICADE,1 were not statistically significantly different. INFLECTRA is marketed as INFLECTRA (infliximab-dyyb) in the UnitedStates (U.S.) and under other brand names in some countries.
How do you qualify for free eliquis?
You may be eligible for the Free 30-Day Trial Offer for ELIQUIS® (apixaban) if:You have not previously filled a prescription for ELIQUIS;You have a valid 30-day prescription for ELIQUIS;You are being treated with ELIQUIS for an FDA-approved indication that an HCP has planned for more than 35 days of treatment;More items...
How long does it take to be covered by Pfizer?
You may not be fully protected against COVID-19 until 7 to 14 days after your second dose. Some people who are severely immunocompromised are recommended to have a third dose as part of their primary course. Pfizer can be used for this third dose.
Does Teva Pharmaceuticals have a patient assistance program?
The TEVA PHARMACEUTICALS patient assistance program offers free medication to people who otherwise cannot afford their medications. Patients must meet financial and other program specific criteria to be eligible for assistance.
What are the biosimilars of infliximab?
For example, the biosimilars for infliximab include infliximab-dyyb (Inflectra®), infliximab-abda (Renflexis®), and infliximab-axxq (Avsola™).
What are Pfizer biosimilars?
A research study using human subjects to evaluate biomedical or health-related outcomes. Biologics include a wide range of biologic products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and genetically engineered therapeutic proteins.
Does Pfizer make Inflectra?
Pfizer holds exclusive commercialization rights to Celltrion's INFLECTRA in the U.S., and has already successfully introduced INFLECTRA in other markets across the globe. INFLECTRA will be introduced at a 15% discount to the current wholesaler acquisition cost (WAC) of REMICADE®, its reference product.
Is infliximab on the PBS?
Infliximab is currently listed on the PBS (Section 100 – Highly Specialised Drugs Program) for the treatment of severe active rheumatoid arthritis, active ankylosing spondylitis, severe active psoriatic arthritis, severe refractory Crohn disease; severe chronic plaque psoriasis and refractory fistulising Crohn disease.
How to contact FDA Medwatch?
Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at https://vaers.hhs.gov or call (800) 822-7967.
How much infliximab-dyyb is in a vial?
For injection: 100 mg of infliximab-dyyb as a white lyophilized powder in a single-dose vial for reconstitution and dilution.
How many vials are infliximab-dyyb?
INFLECTRA (infliximab-dyyb) for injection is supplied as one single-dose vial...
What is Pfizer Rxpathways?
Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Patients and physicians can contact RxPathways at (866) 706-2400 or visit the website for more information on these programs www.pfizerrxpathways.com.
What is Infliximab used for?
Inflectra (infliximab) is a member of the TNF alfa inhibitors drug class and is commonly used for Ankylosing Spondylitis, Crohn's Disease, Crohn's Disease - Acute, and others.
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Is Inflectra valid with insurance?
Prices are for cash paying customers only and are not valid with insurance plans. This Inflectra price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
What is the phone number for InflECTRA?
Have been prescribed INFLECTRA® (infl iximab-dyyb) for Injection (For help with any other Pfi zer medicines, or to learn about Pfi zer’s other assistance programs, please call 844-989-PATH (7284) to speak with a Medicine Access Counselor (M-F, 8 AM - 6 PM ET)
What is Pfizer's information?
The information you provide will be used by Pfizer to improve and tailor our products and services to better serve you. The information will 3 also be used by the Pfizer Patient Assistance FoundationTM and parties acting on their behalf to administer and improve Pfizer’s assistance programs, to communicate with you about your experience with Pfizer’s assistance programs, and/or to send you materials and other helpful information and updates relating to Pfizer programs.
What is the function of inflectra?
INFLECTRA blocks the action of a protein in your body called tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is made by your body's immune system. People with certain diseases have too much TNF-alpha that can cause the immune system to attack normal healthy parts of the body. INFLECTRA can block the damage caused by too much TNF-alpha.
What type of cancer is inflected with TNF blockers?
Some people receiving TNF blockers, including INFLECTRA, developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. Most of these people were male teenagers or young men. Also, most people were being treated for Crohn's disease or ulcerative colitis with a TNF blocker and another medicine called azathioprine or 6-mercaptopurine.
What is the name of the medicine that blocks tumor necrosis factor?
There have been cases of unusual cancers in children and teenage patients using tumor necrosis factor (TNF) blocker medicines, such as INFLECTRA.
Is SelectI a healthcare professional?
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
Does plaque psoriasis go away?
Plaque Psoriasis - adult patients with plaque psoriasis that is chronic (does not go away) severe, extensive, and/or disabling.
Can you get cancer from inflextra?
Patients with Chronic Obstructive Pulmonary Disease (COPD), a specific type of lung disease, may have an increased risk for getting cancer while being treated with INFLECTRA.
Does Infliximab cause cancer?
Some people treated with infliximab products, such as INFLECTRA, have developed certain kinds of skin cancer. If any changes in the appearance of your skin or growths on your skin occur during or after your treatment with INFLECTRA, tell your doctor.
What is Inflectra used for?from accessdata.fda.gov
Inflectra is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
How long does it take to take Inflectra?from drugs.com
The recommended dose of Inflectra is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of chronic severe (i.e., extensive and/or disabling) plaque psoriasis.
How long does infliximab last?from accessdata.fda.gov
The safety and efficacy of infliximab in patients with juvenile rheumatoid arthritis (JRA) were evaluated in a multicenter, randomized, placebo-controlled, double-blind study for 14 weeks, followed by a double-blind, all-active treatment extension, for a maximum of 44 weeks. Patients with active JRA between the ages of 4 and 17 years who had been treated with MTX for at least 3 months were enrolled. Concurrent use of folic acid, oral corticosteroids (≤0.2 mg/kg/day of prednisone or equivalent), NSAIDs, and/or disease modifying antirheumatic drugs (DMARDs) was permitted.
What are the malignancies associated with TNF blockers?from accessdata.fda.gov
The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months (range 1 to 84 months) after the first dose of TNF blocker therapy. Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.
How long does it take for Infliximab to cause hypersensitivity?from drugs.com
Most hypersensitivity reactions (including anaphylaxis, urticaria, dyspnea, and/or hypotension), have occurred during or within 2 hours of infliximab product infusion.
How safe is Infliximab?from drugs.com
The safety and effectiveness of infliximab products for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients aged 6 years and older with moderately to severely active UC who have had an inadequate response to conventional therapy are supported by evidence from adequate and well-controlled studies of infliximab in adults. Additional safety and pharmacokinetic data were collected in an open-label pediatric UC trial in 60 pediatric patients aged 6 through 17 years (median age 14.5 years) with moderately to severely active UC (Mayo score of 6 to 12; Endoscopic subscore ≥2) and an inadequate response to conventional therapies. At baseline, the median Mayo score was 8, 53% of patients were receiving immunomodulator therapy (6-MP/AZA/MTX), and 62% of patients were receiving corticosteroids (median dose 0.5 mg/kg/day in prednisone equivalents). Discontinuation of immunomodulators and corticosteroid taper were permitted after Week 0.
What infections are treated with Infliximab?from accessdata.fda.gov
The infections most frequently reported were respiratory tract infections (including sinusitis, pharyngitis, and bronchitis) and urinary tract infections. Among patients treated with infliximab, serious infections included pneumonia, cellulitis, abscess, skin ulceration, sepsis, and bacterial infection. In clinical trials, 7 opportunistic infections were reported; 2 cases each of coccidioidomycosis (1 case was fatal) and histoplasmosis (1 case was fatal), and 1 case each of pneumocystosis, nocardiosis and cytomegalovirus. Tuberculosis was reported in 14 patients, 4 of whom died due to miliary tuberculosis. Other cases of tuberculosis, including disseminated tuberculosis, also have been reported postmarketing. Most of these cases of tuberculosis occurred within the first 2 months after initiation of therapy with infliximab and may reflect recrudescence of latent disease [see Warnings and Precautions (5.1)]. In the 1-year placebo-controlled studies RA I and RA II, 5.3% of patients receiving infliximab every 8 weeks with methotrexate (MTX) developed serious infections as compared to 3.4% of placebo patients receiving MTX. Of 924 patients receiving infliximab, 1.7% developed pneumonia and 0.4% developed tuberculosis, when compared to 0.3% and 0.0% in the placebo arm respectively. In a shorter (22-week) placebo-controlled study of 1082 RA patients randomized to receive placebo, 3 mg/kg or 10 mg/kg infusions with infliximab at 0, 2, and 6 weeks, followed by every 8 weeks with MTX, serious infections were more frequent in the 10 mg/kg infliximab group (5.3%) than the 3 mg/kg or placebo groups (1.7% in both). During the 54-week Crohn's II Study, 15% of patients with fistulizing Crohn's disease developed a new fistula-related abscess.
